{"id":55101,"date":"2026-01-22T10:19:12","date_gmt":"2026-01-22T02:19:12","guid":{"rendered":"https:\/\/flcube.com\/?p=55101"},"modified":"2026-01-22T10:19:13","modified_gmt":"2026-01-22T02:19:13","slug":"bioray-pharmaceutical-files-hkex-ipo-backed-by-first-in-class-autoimmune-and-oncology-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55101","title":{"rendered":"BioRay Pharmaceutical Files HKEX IPO, Backed by First\u2011in\u2011Class Autoimmune and Oncology Pipeline"},"content":{"rendered":"\n<p><strong>Zhejiang-based BioRay Pharmaceutical Co., Ltd<\/strong> announced an <strong>initial public offering (IPO) filing<\/strong> to the <strong>Hong Kong Stock Exchange<\/strong>, seeking to raise capital to advance its <strong>portfolio of eight commercialized products<\/strong> led by <strong>first\u2011in\u2011class and best\u2011in\u2011class assets<\/strong> including <strong>Bimzelx (bimekizumab), Anruixi (zuberitamab), and BR2251<\/strong>, positioning the company to reshape treatment paradigms in <strong>autoimmune diseases and oncology<\/strong> in China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>BioRay Pharmaceutical Co., Ltd (Zhejiang\u2011based)<\/td><\/tr><tr><td><strong>Event<\/strong><\/td><td>Initial Public Offering (IPO) filing<\/td><\/tr><tr><td><strong>Exchange<\/strong><\/td><td>Hong Kong Stock Exchange<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>Week of 20\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Advance commercialized portfolio, fund R&amp;D, expand manufacturing<\/td><\/tr><tr><td><strong>Product Pipeline<\/strong><\/td><td>8 commercialized products, 3 lead first\u2011in\u2011class\/best\u2011in\u2011class assets<\/td><\/tr><tr><td><strong>Strategic Focus<\/strong><\/td><td>Transition to innovation\u2011driven biopharma with proprietary technologies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-product-portfolio\">Core Product Portfolio<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Target\/Mechanism<\/th><th>Status<\/th><th>Indication<\/th><th>Market Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Bimzelx (bimekizumab)<\/strong><\/td><td>IL\u201117A\/F inhibitor<\/td><td>Commercialized<\/td><td>Autoimmune (psoriasis, arthritis)<\/td><td>First\u2011in\u2011class\/best\u2011in\u2011class in China<\/td><\/tr><tr><td><strong>Anruixi (zuberitamab)<\/strong><\/td><td>CD20 monoclonal antibody<\/td><td>Commercialized<\/td><td>Hematologic malignancies<\/td><td><strong>China\u2019s first Category\u202f1 innovative CD20 mAb<\/strong><\/td><\/tr><tr><td><strong>BR2251<\/strong><\/td><td>Novel gout drug (differentiated MOA)<\/td><td>Commercialized<\/td><td>Gout<\/td><td><strong>Potential first\u2011in\u2011class\/best\u2011in\u2011class<\/strong><\/td><\/tr><tr><td><strong>Other Assets<\/strong><\/td><td>Undisclosed<\/td><td>Commercialized<\/td><td>Autoimmune\/oncology<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China Market<\/th><th>Global Market<\/th><\/tr><\/thead><tbody><tr><td><strong>Autoimmune Market (2030E)<\/strong><\/td><td>\u00a5180\u202fbillion<\/td><td>$180\u202fbillion<\/td><\/tr><tr><td><strong>CD20 mAb Market (2030E)<\/strong><\/td><td>\u00a525\u202fbillion<\/td><td>$15\u202fbillion<\/td><\/tr><tr><td><strong>Gout Market (2030E)<\/strong><\/td><td>\u00a512\u202fbillion<\/td><td>$8\u202fbillion<\/td><\/tr><tr><td><strong>Bimzelx Peak Share<\/strong><\/td><td>12%<\/td><td>3%<\/td><\/tr><tr><td><strong>Anruixi Peak Share<\/strong><\/td><td>18%<\/td><td>2%<\/td><\/tr><tr><td><strong>BR2251 Peak Share<\/strong><\/td><td>15%<\/td><td>1%<\/td><\/tr><tr><td><strong>Combined Peak Revenue (2032E)<\/strong><\/td><td>\u00a548\u202fbillion ($6.8\u202fbillion)<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IL\u201117 Inhibitors:<\/strong> Cosentyx (Novartis), Taltz (Lilly), Skyrizi (AbbVie) \u2013 Bimzelx\u2019s <strong>dual IL\u201117A\/F blockade<\/strong> offers <strong>superior skin clearance<\/strong> vs. monospecific agents<\/li>\n\n\n\n<li><strong>CD20 mAbs:<\/strong> Rituxan (Roche), Gazyva (Roche) \u2013 Anruixi\u2019s <strong>Category\u202f1 innovation<\/strong> qualifies for <strong>NRDL fast\u2011track<\/strong> and <strong>premium pricing<\/strong><\/li>\n\n\n\n<li><strong>Gout Therapies:<\/strong> Allopurinol (generic), febuxostat (Takeda) \u2013 BR2251\u2019s <strong>differentiated mechanism<\/strong> targets <strong>refractory patients<\/strong> with <strong>renal impairment<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-synergies\">Strategic Positioning &amp; Synergies<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> BioRay\u2019s <strong>Hangzhou biologics facility<\/strong> (capacity 20,000\u202fL) supports Bimzelx and Anruixi production; <strong>BR2251 small\u2011molecule plant<\/strong> (10\u202fton\/year) ensures supply chain control<\/li>\n\n\n\n<li><strong>R&amp;D Platform:<\/strong> Transitioning from <strong>validated molecule developer<\/strong> to <strong>innovation\u2011driven biopharma<\/strong> with <strong>proprietary ADC and bispecific platforms<\/strong><\/li>\n\n\n\n<li><strong>Commercial Reach:<\/strong> <strong>3,000\u2011hospital network<\/strong> established for Bimzelx; <strong>cross\u2011selling<\/strong> Anruixi and BR2251 leverages existing relationships<\/li>\n\n\n\n<li><strong>Licensing Strategy:<\/strong> Retains <strong>Greater China rights<\/strong> for core assets; seeking <strong>ex\u2011China partnerships<\/strong> for <strong>BR2251<\/strong> (US\/EU rights potential value $800\u202fM)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding IPO completion, market penetration, and revenue forecasts for BioRay\u2019s product portfolio. Actual results may differ due to competitive responses, regulatory approvals, and market access dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26010600491.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26010600491.\"><\/object><a id=\"wp-block-file--media-72d00373-624f-4fa5-8f8e-d2f93f17747f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26010600491.pdf\">sehk26010600491<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26010600491.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-72d00373-624f-4fa5-8f8e-d2f93f17747f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zhejiang-based BioRay Pharmaceutical Co., Ltd announced an initial public offering (IPO) filing to the Hong&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55102,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2575,72],"class_list":["post-55101","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-bioray-pharmaceutical","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BioRay Pharmaceutical Files HKEX IPO, Backed by First\u2011in\u2011Class Autoimmune and Oncology Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhejiang-based BioRay Pharmaceutical Co., Ltd announced an initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking to raise capital to advance its portfolio of eight commercialized products led by first\u2011in\u2011class and best\u2011in\u2011class assets including Bimzelx (bimekizumab), Anruixi (zuberitamab), and BR2251, positioning the company to reshape treatment paradigms in autoimmune diseases and oncology in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55101\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioRay Pharmaceutical Files HKEX IPO, Backed by First\u2011in\u2011Class Autoimmune and Oncology Pipeline\" \/>\n<meta property=\"og:description\" content=\"Zhejiang-based BioRay Pharmaceutical Co., Ltd announced an initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking to raise capital to advance its portfolio of eight commercialized products led by first\u2011in\u2011class and best\u2011in\u2011class assets including Bimzelx (bimekizumab), Anruixi (zuberitamab), and BR2251, positioning the company to reshape treatment paradigms in autoimmune diseases and oncology in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55101\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T02:19:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T02:19:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2202.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55101#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55101\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BioRay Pharmaceutical Files HKEX IPO, Backed by First\u2011in\u2011Class Autoimmune and Oncology Pipeline\",\"datePublished\":\"2026-01-22T02:19:12+00:00\",\"dateModified\":\"2026-01-22T02:19:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55101\"},\"wordCount\":423,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55101#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2202.webp\",\"keywords\":[\"BioRay Pharmaceutical\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55101#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55101\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55101\",\"name\":\"BioRay Pharmaceutical Files HKEX IPO, Backed by First\u2011in\u2011Class Autoimmune and Oncology Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55101#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55101#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2202.webp\",\"datePublished\":\"2026-01-22T02:19:12+00:00\",\"dateModified\":\"2026-01-22T02:19:13+00:00\",\"description\":\"Zhejiang-based BioRay Pharmaceutical Co., Ltd announced an initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking to raise capital to advance its portfolio of eight commercialized products led by first\u2011in\u2011class and best\u2011in\u2011class assets including Bimzelx (bimekizumab), Anruixi (zuberitamab), and BR2251, positioning the company to reshape treatment paradigms in autoimmune diseases and oncology in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55101#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55101\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55101#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2202.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2202.webp\",\"width\":1080,\"height\":608,\"caption\":\"BioRay Pharmaceutical Files HKEX IPO, Backed by First\u2011in\u2011Class Autoimmune and Oncology Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55101#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioRay Pharmaceutical Files HKEX IPO, Backed by First\u2011in\u2011Class Autoimmune and Oncology Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BioRay Pharmaceutical Files HKEX IPO, Backed by First\u2011in\u2011Class Autoimmune and Oncology Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Zhejiang-based BioRay Pharmaceutical Co., Ltd announced an initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking to raise capital to advance its portfolio of eight commercialized products led by first\u2011in\u2011class and best\u2011in\u2011class assets including Bimzelx (bimekizumab), Anruixi (zuberitamab), and BR2251, positioning the company to reshape treatment paradigms in autoimmune diseases and oncology in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55101","og_locale":"en_US","og_type":"article","og_title":"BioRay Pharmaceutical Files HKEX IPO, Backed by First\u2011in\u2011Class Autoimmune and Oncology Pipeline","og_description":"Zhejiang-based BioRay Pharmaceutical Co., Ltd announced an initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking to raise capital to advance its portfolio of eight commercialized products led by first\u2011in\u2011class and best\u2011in\u2011class assets including Bimzelx (bimekizumab), Anruixi (zuberitamab), and BR2251, positioning the company to reshape treatment paradigms in autoimmune diseases and oncology in China.","og_url":"https:\/\/flcube.com\/?p=55101","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-22T02:19:12+00:00","article_modified_time":"2026-01-22T02:19:13+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2202.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55101#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55101"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BioRay Pharmaceutical Files HKEX IPO, Backed by First\u2011in\u2011Class Autoimmune and Oncology Pipeline","datePublished":"2026-01-22T02:19:12+00:00","dateModified":"2026-01-22T02:19:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55101"},"wordCount":423,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55101#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2202.webp","keywords":["BioRay Pharmaceutical","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55101#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55101","url":"https:\/\/flcube.com\/?p=55101","name":"BioRay Pharmaceutical Files HKEX IPO, Backed by First\u2011in\u2011Class Autoimmune and Oncology Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55101#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55101#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2202.webp","datePublished":"2026-01-22T02:19:12+00:00","dateModified":"2026-01-22T02:19:13+00:00","description":"Zhejiang-based BioRay Pharmaceutical Co., Ltd announced an initial public offering (IPO) filing to the Hong Kong Stock Exchange, seeking to raise capital to advance its portfolio of eight commercialized products led by first\u2011in\u2011class and best\u2011in\u2011class assets including Bimzelx (bimekizumab), Anruixi (zuberitamab), and BR2251, positioning the company to reshape treatment paradigms in autoimmune diseases and oncology in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55101#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55101"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55101#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2202.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2202.webp","width":1080,"height":608,"caption":"BioRay Pharmaceutical Files HKEX IPO, Backed by First\u2011in\u2011Class Autoimmune and Oncology Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55101#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BioRay Pharmaceutical Files HKEX IPO, Backed by First\u2011in\u2011Class Autoimmune and Oncology Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2202.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55101"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55101\/revisions"}],"predecessor-version":[{"id":55106,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55101\/revisions\/55106"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55102"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55101"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55101"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}